Nanoform Finland Feed

2026-03-30 20:10:00 Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026

2026-03-19 19:00:00 Notice to the Annual General Meeting of NANOFORM FINLAND Plc 0,67 EUR | +0,75% | 0,05 MEUR

2026-03-19 19:00:00 Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen 0,67 EUR | +0,75% | 0,05 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – David Rowe 0,72 EUR | -2,70% | 0,09 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 0,72 EUR | -2,70% | 0,09 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Christian Jones 0,72 EUR | -2,70% | 0,09 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström 0,72 EUR | -2,70% | 0,09 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Antonio Da Silva 0,72 EUR | -2,70% | 0,09 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 0,72 EUR | -2,70% | 0,09 MEUR

2026-03-02 07:10:00 The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees 0,72 EUR | -2,70% | 0,09 MEUR

2026-02-26 07:10:00 Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe 0,75 EUR | +1,08% | 0,39 MEUR

2026-02-13 10:00:00 Invitation to Nanoform’s Q4 and FY2025 Report Presentation 0,78 EUR | +1,30% | 0,08 MEUR

2026-02-12 07:00:00 Nanoform - Subcutaneously administered Nanotrastuzumab matches performance of Herceptin HYLECTA in minipig study 0,77 EUR | -0,90% | 0,23 MEUR

2026-02-05 07:05:00 Nanoform Finland Plc’s change negotiations have ended 0,85 EUR | -3,41% | 0,14 MEUR

2026-01-29 18:00:00 Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act 0,88 EUR | -2,11% | 0,20 MEUR

2026-01-07 07:05:00 Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 0,97 EUR | -15,65% | 0,99 MEUR

2025-12-30 10:00:00 Nanoform financial calendar for 2026 1,17 EUR | +1,91% | 0,29 MEUR

2025-12-16 06:00:00 Inside information: Nanoform announces new midterm business targets for 2030 1,08 EUR | +2,27% | 0,26 MEUR

2025-11-13 07:00:00 Nanoform Capital Markets Day December 16th, 2025 1,05 EUR | -5,06% | 0,17 MEUR

2025-11-12 07:10:00 Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set 1,11 EUR | -1,07% | 0,28 MEUR

2025-11-11 07:00:00 Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License 1,12 EUR | +3,71% | 0,41 MEUR

2025-10-29 10:00:00 Invitation to Nanoform’s Q3 2025 Report Presentation 1,15 EUR | +1,41% | 0,08 MEUR

2025-10-27 08:10:00 Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma 1,20 EUR | -2,92% | 0,28 MEUR

2025-10-21 08:00:00 Results of Nanoform Collaborative Study to be Presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) Summit 1,17 EUR | +7,35% | 0,22 MEUR

2025-10-16 15:00:00 Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act 1,08 EUR | -1,10% | 0,08 MEUR

2025-10-14 08:30:00 NANOFORM OUTLICENSES NANOENCORAFENIB AND SIGNS DEVELOPMENT AND COMMERCIALISATION AGREEMENT WITH A.FORALL AND IMGA 1,08 EUR | +1,89% | 0,31 MEUR

2025-09-30 08:30:00 NANOFORM EXPANDS COMMERCIAL PRESENCE IN ASIA WITH A&LS PHARMA IN SOUTH KOREA 1,29 EUR | +18,63% | 1,08 MEUR

2025-09-26 10:00:00 Nanoform Q3 2025 report day set for November 12th, 2025 1,06 EUR | +6,53% | 0,47 MEUR

2025-09-11 07:10:00 Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit 0,83 EUR | -2,79% | 0,06 MEUR

2025-08-21 07:10:00 Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results 0,89 EUR | -7,33% | 0,25 MEUR

2025-08-07 10:00:00 Invitation to Nanoform’s Q2 2025 Report Presentation 0,97 EUR | +0,41% | 0,03 MEUR

2025-06-19 08:00:00 NANOFORM SECURES €5 MILLION R&D LOAN FROM BUSINESS FINLAND TO ADVANCE CLINICAL DEVELOPMENT OF NANOAPALUTAMIDE 1,16 EUR | +2,65% | 0,35 MEUR

2025-06-17 19:32:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 1,13 EUR | +10,78% | 0,46 MEUR

2025-06-17 19:32:00 Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma 1,13 EUR | +10,78% | 0,46 MEUR

2025-06-17 19:32:00 Nanoform Finland Plc – Manager’s Transactions – Miguel Calado 1,13 EUR | +10,78% | 0,46 MEUR

2025-06-17 19:30:00 Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2025 on remuneration of the Board of Directors 1,13 EUR | +10,78% | 0,46 MEUR

2025-06-12 07:10:00 Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide 0,75 EUR | -4,21% | 0,46 MEUR

2025-06-03 07:10:00 DEVELOPMENT OF NANOFORMED TRASTUZUMAB FOR SUBCUTANEOUS INJECTION TO BE PRESENTED AT DDF SUMMIT IN BERLIN 0,89 EUR | -1,11% | 0,07 MEUR

2025-05-30 08:45:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 0,90 EUR | -0,22% | 0,27 MEUR

2025-05-30 08:45:00 Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 0,90 EUR | -0,22% | 0,27 MEUR

2025-05-28 16:00:00 POSITIVE NANOFORM BIOLOGICS RESPIRATORY DATA TO BE PRESENTED AT DRUG DELIVERY AND FORMULATION SUMMIT 0,90 EUR | -5,46% | 0,33 MEUR

2025-05-20 07:10:00 Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS® technology 0,94 EUR | -2,40% | 0,15 MEUR

2025-05-20 06:45:00 INSIDE INFORMATION MADE PUBLIC: NANOFORM PARTNERS WITH TWO SPECIALIST HEALTHCARE INVESTORS TO DEVELOP AND COMMERCIALISE NANOENCORAFENIB 0,94 EUR | -2,40% | 0,15 MEUR

2025-05-06 10:00:00 Invitation to Nanoform’s Q1 2025 Report Presentation 0,98 EUR | -1,50% | 0,07 MEUR

2025-04-15 13:10:00 Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc 1,10 EUR | -1,79% | 0,01 MEUR

2025-04-15 13:00:00 Resolutions of Nanoform Finland Plc's Annual General Meeting on April 15, 2025 1,10 EUR | -1,79% | 0,01 MEUR

2025-03-17 16:15:00 Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen 1,18 EUR | +0,34% | 0,17 MEUR

2025-03-17 16:15:00 Notice to the Annual General Meeting of NANOFORM FINLAND Plc 1,18 EUR | +0,34% | 0,17 MEUR

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Nanoform Finland

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden